Sciele’s Antidrooling Liquid Passes Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Orphan drug fleshes out firm’s fast-growing pediatric division.
You may also be interested in...
Child’s Play: Sciele To Boost Pediatric Presence With Alliant Acquisition
Deal worth $122 million gives Sciele products including Orapred and oral suspension of Allegra.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.